In what ways has tigecycline's patent influenced antibiotic research and development?

Tigecycline’s patent has acted as a catalyst for many of the shifts we see in the antibiotic pipeline today. Below is a quick‑look rundown of the main ways the intellectual‑property (IP) story around tigecycline has shaped research and development (R&D) in the field of antibacterial drugs.

| How | What it means for R&D | Why it matters |
|-----|-----------------------|----------------|
| Strong 20‑year exclusivity | Pfizer (and its partner, Janssen/Johnson & Johnson) held the core “generic‑form” patent (U.S. 5,794,089, 1998) plus a bundle of secondary patents (formulation, delivery, use‑indication, companion diagnostics). | It gave the sponsor a “gold‑mine” period to recover the $4‑$7 billion cost of bringing an antibiotic to market, and to finance the next wave of compounds. |
| Incentivising “next‑generation” glycylcyclines | The patent life of tigecycline created a clear economic path for follow‑on molecules—omadacycline, sarecycline, and eravacycline.